>Globaler Markt für die Vagusnervstimulation, nach Produkttyp (implantierbare VNS-Geräte und externe VNS-Geräte), Biomaterial ( Keramik, Metall und Polymer), Anwendung (Schmerzbehandlung, epileptische Anfälle, Behandlung von Fettleibigkeit, Depression und Angst usw.), Patiententyp (Erwachsene, Kinder und Geriatrie), Endbenutzer (Krankenhäuser, ambulante Operationszentren, Fachzentren usw.), Vertriebskanal (direkte Ausschreibung, Einzelhandel usw.) – Branchentrends und Prognose bis 2029.
Marktanalyse und Erkenntnisse zur Vagusnervstimulation
Der Vagusnerv ist ein wichtiger Bestandteil des autonomen Nervensystems, der die metabolische Homöostase reguliert und als entscheidender Bestandteil der neuroendokrin-immunen Achse bei der Aufrechterhaltung der Homöostase über seine afferenten und efferenten Bahnen fungiert. Jeder Ansatz, der den Vagusnerv stimuliert, einschließlich manueller oder elektrischer Stimulation, wird als Vagusnervstimulation (VNS) bezeichnet. Bei refraktärer Epilepsie und behandlungsresistenter Depression ist die linkszervikale VNS eine zugelassene Therapie.
Laut WHO sind neurologische Erkrankungen für 4,5 bis 11 Prozent aller Erkrankungen weltweit verantwortlich. Vagusnervstimulatoren werden auch zur Behandlung von Patienten mit Epilepsie, Depressionen, Asthma und Herz-Kreislauf-Erkrankungen eingesetzt.
Der globale Markt für Vagusnervstimulation wird im Prognosezeitraum von 2022 bis 2029 voraussichtlich wachsen. Data Bridge Market Research analysiert, dass der Markt im Prognosezeitraum von 2022 bis 2029 mit einer CAGR von 15,0 % wächst und bis 2029 voraussichtlich 2.424,01 Millionen USD erreichen wird.
|
Berichtsmetrik |
Details |
|
Prognosezeitraum |
2022 bis 2029 |
|
Basisjahr |
2021 |
|
Historisches Jahr |
2020 (Anpassbar auf 2019 – 2014) |
|
Quantitative Einheiten |
Umsatz in Mio. USD |
|
Abgedeckte Segmente |
Nach Produkttyp (implantierbare VNS-Geräte und externe VNS-Geräte), Biomaterial (Keramik, Metall und Polymer), Anwendung (Schmerzbehandlung, epileptische Anfälle, Behandlung von Übergewicht, Depression und Angst und andere), Patiententyp (Erwachsene, Kinder und Geriatrie), Endbenutzer (Krankenhäuser, ambulante chirurgische Zentren, Fachzentren und andere). |
|
Abgedeckte Länder |
USA, Kanada, Mexiko, Deutschland, Frankreich, Großbritannien, Italien, Spanien, Niederlande, Russland, Schweiz, Türkei, Belgien, restliches Europa, China, Japan, Indien, Südkorea, Australien, Singapur, Thailand, Malaysia, Indonesien, Philippinen, restlicher asiatisch-pazifischer Raum, Brasilien, Argentinien, Kolumbien, restliches Südamerika, Südafrika, Saudi-Arabien, Vereinigte Arabische Emirate, Ägypten, Israel und restlicher Naher Osten und Afrika. |
|
Abgedeckte Marktteilnehmer |
Unter anderem Medtronic, LivaNova PLC, electroCore, Inc., Cirtec, Brain Control Co. Limited, Soterix Medical Inc., SetPoint Medical, MicroTransponder Inc., Parasym Ltd. und tVNS Technologies GmbH. |
Marktdefinition: Globaler Markt für Vagusnervstimulation
Der Vagusnerv ist ein langer Hirnnerv, der vom Hirnstamm in den Hals, die Brust und den Bauch eines Menschen verläuft. Er ist Teil des parasympathischen Nervensystems, das allgemein als Ruhe- und Verdauungssystem bezeichnet wird, da es die Körperfunktionen reguliert, während sich ein Mensch im Ruhezustand befindet. Er übermittelt Nachrichten aus dem Verdauungssystem und Organen wie Lunge, Herz und Leber an das Gehirn eines Menschen. Er steuert mehrere Organfunktionen, darunter Verdauung, Herzfrequenz und Atemfrequenz. Er ist für die vasomotorische Aktivität und Reflexe verantwortlich. Er reguliert auch die Stimmgebung, Stimmung und Immunität. Er beeinflusst auch die sensorischen Funktionen in den Ohren, Nebenhöhlen und der Speiseröhre eines Menschen.
Bei VNS wird ein Impulsgenerator unter die Haut auf der Brust einer Person eingesetzt. Das implantierbare Gerät, das einem Herzschrittmacher ähnelt, sendet über den Vagusnerv regelmäßige elektrische Impulse an das Gehirn. Eine zusätzliche Stimulation ist möglich, indem der mitgelieferte Magnet über den Impulsgenerator gelegt wird. Entspannungstechniken wie Atemübungen, Yoga und Medikamente können die Aktivität des Vagusnervs beeinflussen und seine Fähigkeit verbessern, Angstzustände und stimmungsbedingte Symptome zu lindern. VNS kann die körperliche Gesundheit einer Person verbessern und bei verschiedenen Erkrankungen wie Epilepsie und Depressionen hilfreich sein. Die Behandlung hat eine heilende Wirkung auf den Körper einer Person, da sie Entspannung fördert und Entzündungen reduziert.
Marktdynamik: Globaler Markt für Vagusnervstimulation
Treiber
- Zunehmende Prävalenz und Inzidenz neurologischer Erkrankungen
Neurologische Störungen verursachen 4,5 % bis 11 % aller Krankheiten, egal ob in Ländern mit niedrigem oder hohem Einkommen. Die Auswirkungen sind größer als bei Krebserkrankungen, Magen-Darm-Erkrankungen oder Atemwegserkrankungen und werden in den nächsten Jahren voraussichtlich zunehmen. In den USA haben neurologische Erkrankungen ebenfalls stark zugenommen und in den nächsten 20 Jahren wird sich dieser Wachstumstrend voraussichtlich fortsetzen. Die Prävalenz dieser neurologischen Erkrankungen liegt Berichten zufolge zwischen 0,9 % und 4 % (970–4100 pro 100.000 Einwohner), im Durchschnitt bei etwa 2,3 % (2390 pro 100.000 Einwohner). Eine der häufigsten neurologischen Erkrankungen, Epilepsie, betrifft fast jedes Land der Erde. Die meisten Menschen mit dieser Krankheit sind in Ländern wie China und Indien anzutreffen. Aufgrund dieser steigenden Prävalenz steigt die Nachfrage nach verschiedenen Werkzeugen und Behandlungen wie VNS. Immer mehr neurologische Probleme werden mit VNS behandelt. Zusätzlich zu anderen klinischen Anwendungen unterstützt es die Behandlung neurologischer Erkrankungen wie Epilepsie und Depression, da neurologische Erkrankungen weltweit sehr häufig sind.
- Einführung innovativer nicht-invasiver Geräte zur Vagusnervstimulation zur Deckung der Nachfrage
Herkömmliche und konventionelle VNS-Geräte werden in den Körper des Patienten implantiert und an den Vagusnerven werden Leitungen angebracht, die bei Bedarf elektrische Stimulation bieten. Die wachsende Nachfrage und der technologische Fortschritt bei innovativen Geräten führten zur Einführung kleiner implantierbarer VNS-Geräte auf dem Markt. Diese kleinen implantierbaren Geräte bieten Patienten und Gesundheitsdienstleistern verschiedene klinische Vorteile. Die Einführung innovativer Geräte dürfte das Marktwachstum ankurbeln.
Der ständige Fokus der Marktteilnehmer auf Innovation und die Einführung neuer Produkte hat zur Entstehung nichtinvasiver VNS-Geräte (nVNS) auf dem Markt geführt. Diese Geräte werden auch als transkutane VNS-Geräte (tVNS) bezeichnet.
- Anstieg der Produktzulassungen
Die Zulassung von VNS-Geräten unterliegt den Aufsichtsbehörden der US-amerikanischen und der EU-Zulassungsbehörde FDA. Die FDA stellt ein endgültiges Protokoll für die Einreichung eines Antrags auf Zulassung vor der Markteinführung (Pre-Market Approval Application, PMA) oder eine Mitteilung über die Fertigstellung eines Produktentwicklungsprotokolls (Product Development Protocol, PDP) aus.
Zum Beispiel,
Die FDA hat einen implantierbaren Vagusnervstimulator zur Behandlung von Epilepsie und Depression zugelassen. Darüber hinaus wurden in Europa neue nVNS-Geräte zur Behandlung von Epilepsie, Depression und Schmerzen zugelassen, die keine chirurgische Implantation erfordern.
Die Zulassung für VNS-Geräte würde bedeuten, dass das Gerät als sicher in der Anwendung gilt und für die Zulassung nach der Markteinführung bereit ist. Dies würde zur Lieferung und Verteilung von MRT-Geräten in den Entwicklungsmärkten in Europa und den USA führen. Daher wird erwartet, dass der Anstieg der Produktzulassungen das Marktwachstum ankurbelt.
- Produktentwicklung in den letzten Jahren
Kombinationstherapien sind viel wirksamer als Monotherapien und haben keine zusätzlichen Nebenwirkungen. Sie sind eine sichere und wirksame Alternative für Personen mit therapieresistenten Blasenerkrankungen. Die Kombination verschiedener zielgerichteter Therapiestrategien ist der beste Ansatz zur Linderung von Blasenbeschwerden bei Patienten. Für die therapieresistente Behandlung der Patienten sollten orale Medikamente und Verhaltenstherapie in Betracht gezogen werden. Es stehen verschiedene fortschrittliche zielgerichtete Therapien zur Verfügung, wie z. B. sakrale Neuromodulation, intratrusorische Injektion von Botulinumtoxin A und perkutane Tibianervstimulation. Dies sind fortschrittliche Behandlungen und im Vergleich zu oralen Mitteln wirksamer.
Gelegenheiten
Strategische Initiativen der wichtigsten Marktteilnehmer
Die Nachfrage nach VNS-Geräten steigt auf dem Markt aufgrund der erhöhten F&E-Intensität; außerdem wird das Marktwachstum durch den Wunsch nach innovativen Medikamenten unterstützt. Daher haben die führenden Marktteilnehmer neue Strategien umgesetzt, indem sie neue Geräte und Ausrüstungen entwickelt und mit anderen Marktteilnehmern zusammengearbeitet haben, um den Geschäftsbetrieb und die Rentabilität zu verbessern.
Die weltweit in diesem Markt tätigen Unternehmen verfolgen die Strategie der Zusammenarbeit, um ihr Produktportfolio mit fortschrittlichen, technologiereichen Produkten zu erweitern und ihr Geschäft in vielerlei Hinsicht anzukurbeln. Daher ist zu erwarten, dass die zunehmenden strategischen Initiativen wichtiger Marktteilnehmer den auf dem Markt tätigen Marktteilnehmern erhebliche Chancen bieten.
Zunehmende staatliche Initiativen für neurologische Erkrankungen
Der Zweck der Finanzierung von VNS-Geräten besteht darin, Anwendungen zu fördern, die Geräte für verschiedene neurologische Störungen entwickeln möchten. Neuartige Geräte sollten über die bestehende elektrische oder magnetische Stimulation hinausgehen und neue Stimulationstechniken entwickeln, die eine höhere räumlich-zeitliche Präzision sowie multifokale, geschlossene Kreislaufansätze ermöglichen. Daher würde die Finanzierung durch die Regierung zur Sicherheit des Patienten und zu Kosteneinsparungen führen. Darüber hinaus könnten Krankenhäuser und Gesundheitsbehörden diese Behandlung durch die Zusammenarbeit mit Regierungsorganisationen zu einem niedrigeren Preis durchführen. Daher werden die Fortschritte bei F&E-Aktivitäten und die Finanzierung durch die Regierung eine Chance für dieses Marktwachstum darstellen.
Einschränkung/Herausforderung
- Hohe Wartungs- und Gerätekosten hemmen die Einführung von Vagusnervstimulatoren
Der Kostenanstieg bei VNS-Geräten ist auf die technologische Entwicklung und die gestiegene Nachfrage nach nVNS-Geräten durch Neurologen in Krankenhäusern, Kliniken, Pflegeeinrichtungen und ambulanten chirurgischen Zentren zurückzuführen. Die Gemeinkosten können erklären, warum Krankenhäuser so viel für Stimulationsgeräte verlangen. Die zunehmende Komplexität und die Kosten von VNS-Geräten, technologische Innovationen und robuste Investitionen würden die Kosten erhöhen. Die erhöhten Kosten würden zu einer verzögerten Behandlung von Patienten in Krankenhäusern und Kliniken führen. Daher wird erwartet, dass die gestiegenen Kosten von VNS-Geräten das Marktwachstum bremsen werden.
Auswirkungen von COVID-19 auf den globalen Markt für Vagusnervstimulation
Der COVID-19-Ausbruch hatte drastische Auswirkungen auf das globale Gesundheitswesen, wobei die USA zu den am stärksten betroffenen Ländern gehörten. Die Pandemie wirkte sich negativ auf das Marktwachstum aus, da die Forschungsaktivitäten in diesem Bereich vorübergehend eingestellt wurden und die Zahl der Patienten in Krankenhäusern und Diagnosezentren gering war.
Die Hersteller treffen verschiedene strategische Entscheidungen, um nach COVID-19 wieder auf die Beine zu kommen. Die Akteure führen zahlreiche F&E-Aktivitäten, Produkteinführungen und strategische Partnerschaften durch, um die Technologie und Testergebnisse auf dem Markt für pharmakogenetische Tests zu verbessern.
Jüngste Entwicklung
- Im Mai 2022 gab electroCore, Inc. bekannt, dass der nicht-invasive Vagusnervstimulator gammaCore Sapphire an 130 Standorten der National Spine and Pain Centers (NSPC) in den USA für Patienten mit Schmerzen im Zusammenhang mit verschiedenen Formen primärer Kopfschmerzen erhältlich sein wird. Dies würde dem Unternehmen helfen, mehr Umsatz zu erzielen.
Globaler Marktumfang für Vagusnervstimulation
Der globale Markt für Vagusnervstimulation ist in sechs wichtige Segmente unterteilt, basierend auf Produkttyp, Biomaterial, Anwendung, Patiententyp, Endbenutzer und Vertriebskanal. Das Wachstum dieser Segmente hilft Ihnen bei der Analyse schwacher Wachstumssegmente in den Branchen und bietet den Benutzern einen wertvollen Marktüberblick und Markteinblicke, um strategische Entscheidungen zur Identifizierung der wichtigsten Marktanwendungen zu treffen.
Produkttyp
- Implantierbare VNS-Geräte
- Externe VNS-Geräte
Basierend auf dem Produkttyp ist der Markt in implantierbare VNS-Geräte und externe VNS-Geräte segmentiert.
Biomaterial
- Keramik
- Metallisch
- Polymer
Basierend auf Biomaterialien ist der Markt in Keramik, Metall und Polymer segmentiert.
Anwendung
- Schmerztherapie
- Epileptische Anfälle
- Adipositas-Management
- Depression und Angst
- Sonstiges
Basierend auf der Anwendung ist der Markt in Schmerzbehandlung, epileptische Anfälle, Adipositas-Behandlung, Depressionen und Angstzustände und andere segmentiert.
Patiententyp
- Erwachsene
- Pädiatrie
- Geriatrie
Basierend auf dem Patiententyp ist der Markt in Erwachsene, Kinder und Geriatrie segmentiert.
Endbenutzer
- Krankenhaus
- Ambulante Chirurgiezentren
- Spezialzentren
- Sonstiges
Basierend auf dem Endbenutzer ist der Markt in Krankenhäuser, ambulante Operationszentren, Fachzentren und andere segmentiert.
Vertriebskanal
- Direkte Ausschreibung
- Einzelhandelsumsätze
- Sonstiges
Basierend auf dem Vertriebskanal ist der Markt in Direktausschreibungen, Einzelhandelsverkäufe und Sonstiges segmentiert.
Globale Vagusnervstimulation Marktregionale Analyse/Einblicke
Der globale Markt für die Vagusnervstimulation wird analysiert und es werden Einblicke in die Marktgröße und -trends nach Land, Produkttyp, Biomaterial, Anwendung, Patiententyp, Endbenutzer und Vertriebskanal wie oben angegeben bereitgestellt.
Nordamerika dominiert den globalen Markt für Vagusnervstimulation in Bezug auf Marktanteil und Umsatz und wird seine Dominanz im Prognosezeitraum weiter ausbauen. Dies ist auf die hohe Prävalenz und Inzidenz neurologischer Erkrankungen in der Region zurückzuführen, und wachsende F&E-Investitionen und die Einführung neuer Produkte kurbeln das Marktwachstum an.
Der Länderabschnitt des Berichts enthält auch Angaben zu einzelnen marktbeeinflussenden Faktoren und Änderungen der Marktvorschriften, die sich auf die aktuellen und zukünftigen Markttrends auswirken. Datenpunkte wie Neu- und Ersatzverkäufe, demografische Daten des Landes, Krankheitsepidemiologie und Import- und Exportzölle sind einige der wichtigsten Anhaltspunkte, die zur Prognose des Marktszenarios für einzelne Länder verwendet werden. Darüber hinaus werden bei der Prognoseanalyse der Länderdaten die Präsenz und Verfügbarkeit globaler Marken und ihre Herausforderungen aufgrund der Konkurrenz durch lokale und inländische Marken sowie die Auswirkungen der Vertriebskanäle berücksichtigt.
Wettbewerbsumfeld und globale Analyse der Marktanteile zur Vagusnervstimulation
Die Wettbewerbslandschaft des globalen Marktes für Vagusnervstimulation liefert Details nach Wettbewerbern. Die enthaltenen Details sind Unternehmensübersicht, Unternehmensfinanzen, erzielter Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, globale Präsenz, Produktionsstandorte und -anlagen, Produktionskapazitäten, Stärken und Schwächen des Unternehmens, Produkteinführung, Produktbreite und -umfang sowie Anwendungsdominanz. Die oben angegebenen Datenpunkte beziehen sich nur auf den Fokus der Unternehmen in Bezug auf den Markt.
Zu den wichtigsten Akteuren auf dem Markt zählen unter anderem Medtronic, LivaNova PLC, electroCore, Inc., Cirtec, Brain Control Co. Limited, Soterix Medical Inc., SetPoint Medical, MicroTransponder Inc, Parasym Ltd, Neuropix Company Ltd. und tVNS Technologies GmbH.
Forschungsmethodik
Die Datenerfassung und die Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Die wichtigste Forschungsmethode, die das DBMR-Forschungsteam verwendet, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und eine primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören Vendor Positioning Grid, Marktzeitlinienanalyse, Marktübersicht und -leitfaden, Company Positioning Grid, Company Market Share Analysis, Messstandards, Global vs. Regional und Vendor Share Analysis. Bitte fordern Sie bei weiteren Fragen einen Analystenanruf an.
SKU-
Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud
- Interaktives Datenanalyse-Dashboard
- Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
- Zugriff für Research-Analysten für Anpassungen und Abfragen
- Konkurrenzanalyse mit interaktivem Dashboard
- Aktuelle Nachrichten, Updates und Trendanalyse
- Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Inhaltsverzeichnis
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL VAGUS NERVE STIMULATION MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 LIFELINE CURVE , BY PRODUCT TYPE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 KEY STRATEGIC INITIATIVES
5 REGULATIONS OF GLOBAL VAGUS NERVE STIMULATION MARKET
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE AND INCIDENCE OF NEUROLOGICAL DISORDERS
6.1.2 INNOVATIVE NON-INVASIVE VAGUS NERVE STIMULATION DEVICES INTRODUCED TO MEET DEMAND
6.1.3 RISE IN PRODUCT APPROVALS
6.1.4 PRODUCT DEVELOPMENT IN RECENT YEARS
6.2 RESTRAINTS
6.2.1 HIGH MAINTENANCE AND DEVICE COSTS TO RESTRAIN ADOPTION OF VAGUS NERVE STIMULATORS
6.2.2 RISE IN PRODUCT RECALL
6.2.3 UNFAVORABLE REIMBURSEMENT POLICIES
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS
6.3.2 RISING GOVERNMENT INITIATIVES FOR NEUROLOGICAL DISEASE
6.4 CHALLENGES
6.4.1 RISKS ASSOCIATED WITH THE IMPLANTATION OF THESE DEVICES
6.4.2 LACK OF SKILLED HEALTHCARE PROFESSIONALS
6.4.3 STRINGENT REGULATIONS FOR APPROVAL OF MEDICAL DEVICES
7 GLOBAL VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 IMPLANTABLE VNS DEVICE
7.3 EXTERNAL VNS DEVICE
8 GLOBAL VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL
8.1 OVERVIEW
8.2 METALLIC
8.3 POLYMERIC
8.4 CERAMICS
9 GLOBAL VAGUS NERVE STIMULATION MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 EPILEPTIC SEIZURES
9.2.1 IMPLANTABLE VNS DEVICE
9.2.2 EXTERNAL VNS DEVICE
9.3 DEPRESSION AND ANXIETY
9.3.1 IMPLANTABLE VNS DEVICE
9.3.2 EXTERNAL VNS DEVICE
9.4 PAIN MANAGEMENT
9.4.1 IMPLANTABLE VNS DEVICE
9.4.2 EXTERNAL VNS DEVICE
9.5 OBESITY MANAGEMENT
9.5.1 IMPLANTABLE VNS DEVICE
9.5.2 EXTERNAL VNS DEVICE
9.6 OTHERS
10 GLOBAL VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE
10.1 OVERVIEW
10.2 ADULTS
10.2.1 IMPLANTABLE VNS DEVICES
10.2.2 EXTERNAL VNS DEVICES
10.3 GERIATRIC
10.3.1 IMPLANTABLE VNS DEVICES
10.3.2 EXTERNAL VNS DEVICES
10.4 PEDIATRIC
10.4.1 IMPLANTABLE VNS DEVICES
10.4.2 EXTERNAL VNS DEVICES
11 GLOBAL VAGUS NERVE STIMULATION MARKET, BY END USER
11.1 OVERVIEW
11.2 SPECIALTY CENTERS
11.3 HOSPITALS
11.4 AMBULATORY SURGICAL CENTERS (ASCS)
11.5 OTHERS
12 GLOBAL VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
12.4 OTHERS
13 GLOBAL VAGUS NERVE STIMULATION MARKET, BY REGION
13.1 OVERVIEW
13.2 NORTH AMERICA
13.2.1 U.S.
13.2.2 CANADA
13.2.3 MEXICO
13.3 EUROPE
13.3.1 GERMANY
13.3.2 U.K.
13.3.3 ITALY
13.3.4 SPAIN
13.3.5 FRANCE
13.3.6 SWITZERLAND
13.3.7 BELGIUM
13.3.8 NETHERLANDS
13.3.9 RUSSIA
13.3.10 TURKEY
13.3.11 REST OF EUROPE
13.4 ASIA-PACIFIC
13.4.1 CHINA
13.4.2 JAPAN
13.4.3 SOUTH KOREA
13.4.4 INDIA
13.4.5 AUSTRALIA
13.4.6 SINGAPORE
13.4.7 THAILAND
13.4.8 MALAYSIA
13.4.9 INDONESIA
13.4.10 PHILIPPINES
13.4.11 REST OF ASIA-PACIFIC
13.5 SOUTH AMERICA
13.5.1 BRAZIL
13.5.2 ARGENTINA
13.5.3 COLOMBIA
13.5.4 REST OF SOUTH AFRICA
13.6 MIDDLE EAST AND AFRICA
13.6.1 SOUTH AFRICA
13.6.2 UAE
13.6.3 EGYPT
13.6.4 SAUDI ARABIA
13.6.5 ISRAEL
13.6.6 REST OF MIDDLE EAST AND AFRICA
14 GLOBAL VAGUS NERVE STIMULATION MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: GLOBAL
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
14.3 COMPANY SHARE ANALYSIS: EUROPE
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 ELECTROCORE, INC.
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 LIVANOVA PLC
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 MEDTRONIC
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 SETPOINT MEDICAL
16.4.1 COMPANY SNAPSHOT
16.4.2 COMPANY SHARE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENTS
16.5 TVNS TECHNOLOGIES GMBH
16.5.1 COMPANY SNAPSHOT
16.5.2 COMPANY SHARE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENT
16.6 NEUROPIX COMPANY LTD.
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENT
16.7 BRAIN CONTROL CO. LTD
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENTS
16.8 CIRTEC
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENTS
16.9 MICROTRANSPONDER INC.
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 PARASYM LTD
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENT
16.11 RESHAPE LIFESCIENCES INC. (2021)
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENT
16.12 SOTERIX MEDICAL INC.
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.13 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
Tabellenverzeichnis
TABLE 1 GLOBAL VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 2 GLOBAL IMPLANTABLE VNS DEVICES IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 GLOBAL EXTERNAL VNS DEVICES IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 GLOBAL VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 5 GLOBAL METALLIC IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 GLOBAL POLYMERIC IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 GLOBAL CERAMICS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 GLOBAL VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 9 GLOBAL EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 GLOBAL EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 11 GLOBAL DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 GLOBAL DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 13 GLOBAL PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 GLOBAL PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 15 GLOBAL OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 GLOBAL OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 17 GLOBAL OTHERS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 GLOBAL VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 19 GLOBAL ADULTS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 GLOBAL ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 21 GLOBAL GERIATRICS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 GLOBAL GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 23 GLOBAL PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 GLOBAL PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 25 GLOBAL VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 26 GLOBAL SPECIALTY CENTERS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 GLOBAL HOSPITALS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 GLOBAL AMBULATORY SURGICAL CENTERS (ASCS) IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 GLOBAL OTHERS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 GLOBAL VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 31 GLOBAL DIRECT TENDER IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 GLOBAL RETAIL SALES IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 GLOBAL OTHERS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 GLOBAL VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 NORTH AMERICA VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 36 NORTH AMERICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 37 NORTH AMERICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 38 NORTH AMERICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 39 NORTH AMERICA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 40 NORTH AMERICA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 41 NORTH AMERICA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 42 NORTH AMERICA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 43 NORTH AMERICA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 44 NORTH AMERICA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 45 NORTH AMERICA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 46 NORTH AMERICA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 47 NORTH AMERICA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 48 NORTH AMERICA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 49 NORTH AMERICA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 50 NORTH AMERICA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 51 U.S. VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 52 U.S. VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 53 U.S. VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 54 U.S. VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 55 U.S. VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 56 U.S. EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 57 U.S. DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 58 U.S. PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 59 U.S. OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 60 U.S. VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 61 U.S. ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 62 U.S. GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 63 U.S. PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 64 U.S. VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 65 U.S. VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 66 CANADA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 67 CANADA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 68 CANADA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 69 CANADA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 70 CANADA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 71 CANADA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 72 CANADA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 73 CANADA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 74 CANADA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 75 CANADA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 76 CANADA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 77 CANADA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 78 CANADA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 79 CANADA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 80 CANADA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 81 MEXICO VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 82 MEXICO VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 83 MEXICO VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 84 MEXICO VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 85 MEXICO VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 86 MEXICO EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 87 MEXICO DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 88 MEXICO PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 89 MEXICO OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 90 MEXICO VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 91 MEXICO ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 92 MEXICO GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 93 MEXICO PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 94 MEXICO VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 95 MEXICO VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 96 EUROPE VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 97 EUROPE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 98 EUROPE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 99 EUROPE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 100 EUROPE VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 101 EUROPE VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 102 EUROPE EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 103 EUROPE DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 104 EUROPE PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 105 EUROPE OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 106 EUROPE VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 107 EUROPE ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 108 EUROPE GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 109 EUROPE PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 110 EUROPE VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 111 EUROPE VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 112 GERMANY VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 113 GERMANY VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 114 GERMANY VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 115 GERMANY VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 116 GERMANY VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 117 GERMANY EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 118 GERMANY DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 119 GERMANY PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 120 GERMANY OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 121 GERMANY VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 122 GERMANY ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 123 GERMANY GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 124 GERMANY PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 125 GERMANY VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 126 GERMANY VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 127 U.K. VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 128 U.K. VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 129 U.K. VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 130 U.K. VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 131 U.K. VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 132 U.K. EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 133 U.K. DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 134 U.K. PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 135 U.K. OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 136 U.K. VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 137 U.K. ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 138 U.K. GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 139 U.K. PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 140 U.K. VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 141 U.K. VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 142 ITALY VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 143 ITALY VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 144 ITALY VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 145 ITALY VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 146 ITALY VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 147 ITALY EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 148 ITALY DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 149 ITALY PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 150 ITALY OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 151 ITALY VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 152 ITALY ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 153 ITALY GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 154 ITALY PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 155 ITALY VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 156 ITALY VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 157 SPAIN VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 158 SPAIN VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 159 SPAIN VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 160 SPAIN VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 161 SPAIN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 162 SPAIN EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 163 SPAIN DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 164 SPAIN PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 165 SPAIN OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 166 SPAIN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 167 SPAIN ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 168 SPAIN GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 169 SPAIN PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 170 SPAIN VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 171 SPAIN VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 172 FRANCE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 173 FRANCE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 174 FRANCE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 175 FRANCE VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 176 FRANCE VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 177 FRANCE EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 178 FRANCE DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 179 FRANCE PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 180 FRANCE OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 181 FRANCE VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 182 FRANCE ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 183 FRANCE GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 184 FRANCE PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 185 FRANCE VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 186 FRANCE VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 187 SWITZERLAND VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 188 SWITZERLAND VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 189 SWITZERLAND VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 190 SWITZERLAND VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 191 SWITZERLAND VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 192 SWITZERLAND EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 193 SWITZERLAND DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 194 SWITZERLAND PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 195 SWITZERLAND OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 196 SWITZERLAND VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 197 SWITZERLAND ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 198 SWITZERLAND GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 199 SWITZERLAND PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 200 SWITZERLAND VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 201 SWITZERLAND VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 202 BELGIUM VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 203 BELGIUM VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 204 BELGIUM VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 205 BELGIUM VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 206 BELGIUM VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 207 BELGIUM EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 208 BELGIUM DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 209 BELGIUM PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 210 BELGIUM OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 211 BELGIUM VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 212 BELGIUM ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 213 BELGIUM GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 214 BELGIUM PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 215 BELGIUM VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 216 BELGIUM VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 217 NETHERLANDS VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 218 NETHERLANDS VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 219 NETHERLANDS VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 220 NETHERLANDS VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 221 NETHERLANDS VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 222 NETHERLANDS EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 223 NETHERLANDS DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 224 NETHERLANDS PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 225 NETHERLANDS OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 226 NETHERLANDS VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 227 NETHERLANDS ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 228 NETHERLANDS GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 229 NETHERLANDS PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 230 NETHERLANDS VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 231 NETHERLANDS VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 232 RUSSIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 233 RUSSIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 234 RUSSIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 235 RUSSIA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 236 RUSSIA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 237 RUSSIA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 238 RUSSIA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 239 RUSSIA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 240 RUSSIA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 241 RUSSIA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 242 RUSSIA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 243 RUSSIA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 244 RUSSIA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 245 RUSSIA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 246 RUSSIA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 247 TURKEY VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 248 TURKEY VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 249 TURKEY VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 250 TURKEY VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 251 TURKEY VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 252 TURKEY EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 253 TURKEY DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 254 TURKEY PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 255 TURKEY OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 256 TURKEY VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 257 TURKEY ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 258 TURKEY GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 259 TURKEY PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 260 TURKEY VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 261 TURKEY VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 262 REST OF EUROPE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 263 REST OF EUROPE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 264 REST OF EUROPE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 265 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 266 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 267 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 268 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 269 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 270 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 271 ASIA-PACIFIC EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 272 ASIA-PACIFIC DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 273 ASIA-PACIFIC PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 274 ASIA-PACIFIC OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 275 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 276 ASIA-PACIFIC ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 277 ASIA-PACIFIC GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 278 ASIA-PACIFIC PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 279 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 280 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 281 CHINA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 282 CHINA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 283 CHINA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 284 CHINA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 285 CHINA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 286 CHINA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 287 CHINA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 288 CHINA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 289 CHINA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 290 CHINA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 291 CHINA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 292 CHINA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 293 CHINA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 294 CHINA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 295 CHINA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 296 JAPAN VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 297 JAPAN VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 298 JAPAN VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 299 JAPAN VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 300 JAPAN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 301 JAPAN EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 302 JAPAN DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 303 JAPAN PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 304 JAPAN OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 305 JAPAN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 306 JAPAN ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 307 JAPAN GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 308 JAPAN PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 309 JAPAN VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 310 JAPAN VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 311 SOUTH KOREA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 312 SOUTH KOREA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 313 SOUTH KOREA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 314 SOUTH KOREA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 315 SOUTH KOREA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 316 SOUTH KOREA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 317 SOUTH KOREA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 318 SOUTH KOREA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 319 SOUTH KOREA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 320 SOUTH KOREA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 321 SOUTH KOREA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 322 SOUTH KOREA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 323 SOUTH KOREA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 324 SOUTH KOREA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 325 SOUTH KOREA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 326 INDIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 327 INDIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 328 INDIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 329 INDIA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 330 INDIA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 331 INDIA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 332 INDIA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 333 INDIA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 334 INDIA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 335 INDIA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 336 INDIA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 337 INDIA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 338 INDIA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 339 INDIA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 340 INDIA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 341 AUSTRALIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 342 AUSTRALIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 343 AUSTRALIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 344 AUSTRALIA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 345 AUSTRALIA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 346 AUSTRALIA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 347 AUSTRALIA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 348 AUSTRALIA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 349 AUSTRALIA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 350 AUSTRALIA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 351 AUSTRALIA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 352 AUSTRALIA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 353 AUSTRALIA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 354 AUSTRALIA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 355 AUSTRALIA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 356 SINGAPORE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 357 SINGAPORE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 358 SINGAPORE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 359 SINGAPORE VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 360 SINGAPORE VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 361 SINGAPORE EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 362 SINGAPORE DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 363 SINGAPORE PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 364 SINGAPORE OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 365 SINGAPORE VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 366 SINGAPORE ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 367 SINGAPORE GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 368 SINGAPORE PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 369 SINGAPORE VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 370 SINGAPORE VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 371 THAILAND VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 372 THAILAND VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 373 THAILAND VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 374 THAILAND VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 375 THAILAND VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 376 THAILAND EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 377 THAILAND DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 378 THAILAND PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 379 THAILAND OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 380 THAILAND VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 381 THAILAND ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 382 THAILAND GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 383 THAILAND PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 384 THAILAND VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 385 THAILAND VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 386 MALAYSIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 387 MALAYSIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 388 MALAYSIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 389 MALAYSIA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 390 MALAYSIA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 391 MALAYSIA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 392 MALAYSIA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 393 MALAYSIA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 394 MALAYSIA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 395 MALAYSIA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 396 MALAYSIA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 397 MALAYSIA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 398 MALAYSIA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 399 MALAYSIA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 400 MALAYSIA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 401 INDONESIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 402 INDONESIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 403 INDONESIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 404 INDONESIA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 405 INDONESIA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 406 INDONESIA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 407 INDONESIA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 408 INDONESIA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 409 INDONESIA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 410 INDONESIA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 411 INDONESIA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 412 INDONESIA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 413 INDONESIA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 414 INDONESIA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 415 INDONESIA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 416 PHILIPPINES VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 417 PHILIPPINES VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 418 PHILIPPINES VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 419 PHILIPPINES VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 420 PHILIPPINES VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 421 PHILIPPINES EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 422 PHILIPPINES DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 423 PHILIPPINES PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 424 PHILIPPINES OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 425 PHILIPPINES VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 426 PHILIPPINES ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 427 PHILIPPINES GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 428 PHILIPPINES PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 429 PHILIPPINES VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 430 PHILIPPINES VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 431 REST OF ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 432 REST OF ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 433 REST OF ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 434 SOUTH AMERICA VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 435 SOUTH AMERICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 436 SOUTH AMERICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 437 SOUTH AMERICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 438 SOUTH AMERICA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 439 SOUTH AMERICA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 440 SOUTH AMERICA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 441 SOUTH AMERICA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 442 SOUTH AMERICA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 443 SOUTH AMERICA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 444 SOUTH AMERICA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 445 SOUTH AMERICA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 446 SOUTH AMERICA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 447 SOUTH AMERICA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 448 SOUTH AMERICA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 449 SOUTH AMERICA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 450 BRAZIL VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 451 BRAZIL VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 452 BRAZIL VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 453 BRAZIL VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 454 BRAZIL VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 455 BRAZIL EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 456 BRAZIL DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 457 BRAZIL PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 458 BRAZIL OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 459 BRAZIL VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 460 BRAZIL ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 461 BRAZIL GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 462 BRAZIL PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 463 BRAZIL VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 464 BRAZIL VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 465 ARGENTINA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 466 ARGENTINA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 467 ARGENTINA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 468 ARGENTINA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 469 ARGENTINA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 470 ARGENTINA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 471 ARGENTINA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 472 ARGENTINA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 473 ARGENTINA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 474 ARGENTINA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 475 ARGENTINA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 476 ARGENTINA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 477 ARGENTINA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 478 ARGENTINA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 479 ARGENTINA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 480 COLOMBIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 481 COLOMBIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 482 COLOMBIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 483 COLOMBIA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 484 COLOMBIA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 485 COLOMBIA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 486 COLOMBIA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 487 COLOMBIA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 488 COLOMBIA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 489 COLOMBIA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 490 COLOMBIA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 491 COLOMBIA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 492 COLOMBIA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 493 COLOMBIA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 494 COLOMBIA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 495 REST OF SOUTH AMERICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 496 REST OF SOUTH AMERICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 497 REST OF SOUTH AMERICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 498 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 499 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 500 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 501 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 502 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 503 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 504 MIDDLE EAST AND AFRICA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 505 MIDDLE EAST AND AFRICA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 506 MIDDLE EAST AND AFRICA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 507 MIDDLE EAST AND AFRICA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 508 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 509 MIDDLE EAST AND AFRICA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 510 MIDDLE EAST AND AFRICA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 511 MIDDLE EAST AND AFRICA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 512 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 513 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 514 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 515 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 516 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 517 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 518 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 519 SOUTH AFRICA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 520 SOUTH AFRICA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 521 SOUTH AFRICA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 522 SOUTH AFRICA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 523 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 524 SOUTH AFRICA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 525 SOUTH AFRICA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 526 SOUTH AFRICA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 527 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 528 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 529 UAE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 530 UAE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 531 UAE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 532 UAE VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 533 UAE VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 534 UAE EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 535 UAE DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 536 UAE PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 537 UAE OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 538 UAE VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 539 UAE ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 540 UAE GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 541 UAE PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 542 UAE VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 543 UAE VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 544 EGYPT VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 545 EGYPT VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 546 EGYPT VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 547 EGYPT VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 548 EGYPT VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 549 EGYPT EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 550 EGYPT DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 551 EGYPT PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 552 EGYPT OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 553 EGYPT VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 554 EGYPT ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 555 EGYPT GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 556 EGYPT PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 557 EGYPT VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 558 EGYPT VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 559 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 560 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 561 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 562 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 563 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 564 SAUDI ARABIA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 565 SAUDI ARABIA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 566 SAUDI ARABIA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 567 SAUDI ARABIA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 568 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 569 SAUDI ARABIA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 570 SAUDI ARABIA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 571 SAUDI ARABIA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 572 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 573 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 574 ISRAEL VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 575 ISRAEL VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 576 ISRAEL VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 577 ISRAEL VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 578 ISRAEL VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 579 ISRAEL EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 580 ISRAEL DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 581 ISRAEL PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 582 ISRAEL OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 583 ISRAEL VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 584 ISRAEL ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 585 ISRAEL GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 586 ISRAEL PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 587 ISRAEL VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 588 ISRAEL VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 589 REST OF MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 590 REST OF MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 591 REST OF MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
Abbildungsverzeichnis
FIGURE 1 GLOBAL VAGUS NERVE STIMULATION MARKET: SEGMENTATION
FIGURE 2 GLOBAL VAGUS NERVE STIMULATION MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL VAGUS NERVE STIMULATION MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL VAGUS NERVE STIMULATION MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL VAGUS NERVE STIMULATION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL VAGUS NERVE STIMULATION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL VAGUS NERVE STIMULATION MARKET: DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL VAGUS NERVE STIMULATION MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 GLOBAL VAGUS NERVE STIMULATION MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL VAGUS NERVE STIMULATION MARKET: SEGMENTATION
FIGURE 11 THE GROWING DEMAND FOR INNOVATIVE NON–INVASIVE VAGUS STIMULATION DEVICES AND THE INCREASED PREVALENCE OF NEUROLOGICAL DISORDERS ARE EXPECTED TO DRIVE THE GLOBAL VAGUS NERVE STIMULATION MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 IMPLANTABLE VNS DEVICE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL VAGUS NERVE STIMULATION MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL VAGUS NERVE STIMULATION MARKET, NORTH AMERICA IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR VAGUS NERVE STIMULATION MANUFACTURERS IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL VAGUS NERVE STIMULATION MARKET
FIGURE 16 INCIDENCE OF ADULT-ONSET BRAIN DISORDERS IN THE U.S. IN 2021
FIGURE 17 GLOBAL VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE, 2021
FIGURE 18 GLOBAL VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE, 2022-2029 (USD MILLION)
FIGURE 19 GLOBAL VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE, CAGR (2022-2029)
FIGURE 20 GLOBAL VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 21 GLOBAL VAGUS NERVE STIMULATION MARKET: BY BIOMATERIAL, 2021
FIGURE 22 GLOBAL VAGUS NERVE STIMULATION MARKET: BY BIOMATERIAL, 2022-2029 (USD MILLION)
FIGURE 23 GLOBAL VAGUS NERVE STIMULATION MARKET: BY BIOMATERIAL, CAGR (2022-2029)
FIGURE 24 GLOBAL VAGUS NERVE STIMULATION MARKET: BY BIOMATERIAL, LIFELINE CURVE
FIGURE 25 GLOBAL VAGUS NERVE STIMULATION MARKET: BY APPLICATION, 2021
FIGURE 26 GLOBAL VAGUS NERVE STIMULATION MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 27 GLOBAL VAGUS NERVE STIMULATION MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 28 GLOBAL VAGUS NERVE STIMULATION MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 29 GLOBAL VAGUS NERVE STIMULATION MARKET: BY PATIENT TYPE, 2021
FIGURE 30 GLOBAL VAGUS NERVE STIMULATION MARKET: BY PATIENT TYPE, 2022-2029 (USD MILLION)
FIGURE 31 GLOBAL VAGUS NERVE STIMULATION MARKET: BY PATIENT TYPE, CAGR (2022-2029)
FIGURE 32 GLOBAL VAGUS NERVE STIMULATION MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 33 GLOBAL VAGUS NERVE STIMULATION MARKET: BY END USER, 2021
FIGURE 34 GLOBAL VAGUS NERVE STIMULATION MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 35 GLOBAL VAGUS NERVE STIMULATION MARKET: BY END USER, CAGR (2022-2029)
FIGURE 36 GLOBAL VAGUS NERVE STIMULATION MARKET: BY END USER, LIFELINE CURVE
FIGURE 37 GLOBAL VAGUS NERVE STIMULATION MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 38 GLOBAL VAGUS NERVE STIMULATION MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 39 GLOBAL VAGUS NERVE STIMULATION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 40 GLOBAL VAGUS NERVE STIMULATION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 41 GLOBAL VAGUS NERVE STIMULATION MARKET: SNAPSHOT (2021)
FIGURE 42 GLOBAL VAGUS NERVE STIMULATION MARKET: BY REGION (2021)
FIGURE 43 GLOBAL VAGUS NERVE STIMULATION MARKET: BY REGION (2022 & 2029)
FIGURE 44 GLOBAL VAGUS NERVE STIMULATION MARKET: BY REGION (2021 & 2029)
FIGURE 45 GLOBAL VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE (2022-2029)
FIGURE 46 NORTH AMERICA VAGUS NERVE STIMULATION MARKET: SNAPSHOT (2021)
FIGURE 47 NORTH AMERICA VAGUS NERVE STIMULATION MARKET: BY COUNTRY (2021)
FIGURE 48 NORTH AMERICA VAGUS NERVE STIMULATION MARKET: BY COUNTRY (2022 & 2029)
FIGURE 49 NORTH AMERICA VAGUS NERVE STIMULATION MARKET: BY COUNTRY (2021 & 2029)
FIGURE 50 NORTH AMERICA VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE (2022 - 2029)
FIGURE 51 EUROPE VAGUS NERVE STIMULATION MARKET: SNAPSHOT (2021)
FIGURE 52 EUROPE VAGUS NERVE STIMULATION MARKET: BY COUNTRY (2021)
FIGURE 53 EUROPE VAGUS NERVE STIMULATION MARKET: BY COUNTRY (2022 & 2029)
FIGURE 54 EUROPE VAGUS NERVE STIMULATION MARKET: BY COUNTRY (2021 & 2029)
FIGURE 55 EUROPE VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE (2022 - 2029)
FIGURE 56 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET: SNAPSHOT (2021)
FIGURE 57 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET: BY COUNTRY (2021)
FIGURE 58 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET: BY COUNTRY (2022 & 2029)
FIGURE 59 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET: BY COUNTRY (2021 & 2029)
FIGURE 60 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE (2022 - 2029)
FIGURE 61 SOUTH AMERICA VAGUS NERVE STIMULATION MARKET: SNAPSHOT (2021)
FIGURE 62 SOUTH AMERICA VAGUS NERVE STIMULATION MARKET: BY COUNTRY (2021)
FIGURE 63 SOUTH AMERICA VAGUS NERVE STIMULATION MARKET: BY COUNTRY (2022 & 2029)
FIGURE 64 SOUTH AMERICA VAGUS NERVE STIMULATION MARKET: BY COUNTRY (2021 & 2029)
FIGURE 65 SOUTH AMERICA VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE (2022 - 2029)
FIGURE 66 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET: SNAPSHOT (2021)
FIGURE 67 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET: BY COUNTRY (2021)
FIGURE 68 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET: BY COUNTRY (2022 & 2029)
FIGURE 69 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET: BY COUNTRY (2021 & 2029)
FIGURE 70 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE (2022 - 2029)
FIGURE 71 GLOBAL VAGUS NERVE STIMULATION MARKET: COMPANY SHARE 2021 (%)
FIGURE 72 NORTH AMERICA VAGUS NERVE STIMULATION MARKET: COMPANY SHARE 2021 (%)
FIGURE 73 EUROPE VAGUS NERVE STIMULATION MARKET: COMPANY SHARE 2021 (%)
FIGURE 74 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET: COMPANY SHARE 2021 (%)
Forschungsmethodik
Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.
Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.
Anpassung möglich
Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.
